120 CHF CHF 120.00
AG-CR1-3533-M0011 mgCHF 120.00
AG-CR1-3533-M0055 mgCHF 480.00
C27H32F3N2O2 . I
|MW||473.6 . 126.9|
|Purity Chemicals||≥98% (1H-NMR)|
|Solubility||Soluble in DMSO (50mg/ml), ethanol (50mg/ml) or water (2mg/ml).|
|Identity||Determined by 1H-NMR.|
|Shipping and Handling|
|Short Term Storage||+4°C|
|Long Term Storage||-20°C|
|Handling Advice||Keep cool and dry.|
Stable for at least 2 years after receipt when stored at -20°C.
Stock solutions are stable for at least 3 months when stored at -20°C.
|Product Specification Sheet|
- Potent mitochondrial ATP synthase (ATPases (F0F1)) inhibitor, consequently leading to inhibition of oxidative phosphorylation (OXPHOS).
- Useful agent for immunometabolism research. Inhibits ATP synthase by blocking its proton channel (F0 subunit), which is necessary for oxidative phosphorylation of ADP to ATP (energy production), significantly reducing electron flow through the electron transport chain.
- Potent antitumor agent that inhibits oxidative phosphorylation and consequently growth and proliferation of mouse and human glioblastoma (GBM) with an IC50 of 470nM. Shown to rapidly and irreversibly compromise oxygen consumption in glioblastoma cells. This functional Gboxin analog has excellent metabolic stability, enhanced plasma stability and pharmacokinetic properties, and is suitable for in vivo studies.
- Gboxin-resistant cells require a functional mitochondrial permeability transition pore that regulates pH and thus impedes the accumulation of Gboxin in the mitochondrial matrix. Administration of a metabolically stable Gboxin analog inhibits glioblastoma allografts and patient-derived xenografts. Gboxin toxicity extends to established human cancer cell lines of diverse organ origin and shows that the increased proton gradient and pH in cancer cell mitochondria is a mode of action that can be targeted in the development of antitumor reagents.
- Gboxin is an oxidative phosphorylation inhibitor that targets glioblastoma: Y. Shi, et al.; Nature 567, 341 (2019)